Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

LEO Pharma Gets EU Go-Ahead For Psoriasis Latecomer Brodalumab

Executive Summary

The Danish speciality dermatology company LEO Pharma has achieved a key plank in its plans to provide products for the range of psoriasis patients with an EU go-ahead for brodalumab.

Advertisement

Related Content

Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
Japan To Become First Market For Troubled Brodalumab
Amgen dumps brodalumab; AstraZeneca losing a blockbuster?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel